Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-8448b6f56d-jr42d Total loading time: 0 Render date: 2024-04-19T16:02:37.460Z Has data issue: false hasContentIssue false

Chapter 36 - Uterine Sarcoma and Rare Uterine Malignant Disease

from Section 8 - Uterus

Published online by Cambridge University Press:  24 November 2021

By
Edward Wight
Edited by
Tahir Mahmood ,
Charles Savona-Ventura ,
Ioannis Messinis  and
Sambit Mukhopadhyay
Tahir Mahmood
Affiliation:
Victoria Hospital, Kirkcaldy
Charles Savona-Ventura
Affiliation:
University of Malta, Malta
Ioannis Messinis
Affiliation:
University of Thessaly, Greece
Sambit Mukhopadhyay
Affiliation:
Norfolk & Norwich University Hospital, UK
Get access

Summary

Uterine sarcomas are rare tumours with high recurrence rate and poor prognosis. Only low-grade endometrial stromal sarcomas and adenosarcoma without sarcomatous overgrowth occasionally show an indolent growth, but late recurrences occur even in early-stage disease. Total hysterectomy is the cornerstone of treatment. Tumour-free resection margins after primary surgery and prevention of intra-abdominal spillage of malignant tissue during the intervention are of utmost importance. Removal of the ovaries and retroperitoneal lymph node dissection remain controversial, but oophorectomy is recommended in postmenopausal women and in patients with hormone-sensitive disease. Influence of adjuvant radiotherapy and adjuvant systemic therapy on survival is uncertain, but may be indicated in cases with high risk of recurrence. Palliative systemic therapies comprise doxorubicin alone or in combination with gemcitabine or olaratumab and aromatase inhibitors in hormone-sensitive disease. Encouraging new therapeutic options are beginning to emerge with targeted therapies.

Keywords

uterussarcomacancermalignanttumours
Type
Chapter
Information
The EBCOG Postgraduate Textbook of Obstetrics & Gynaecology
Gynaecology
 , pp. 305 - 316
Publisher: Cambridge University Press
Print publication year: 2021

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Francis, M, Dennis, NL, Hischowitz, L, et al. Incidence and survival of gynaecologic sarcomas in England. Int J Gynecol Cancer 2015;25:850–857.CrossRefGoogle ScholarPubMed
Oliva, E, Carcangiu, ML, Carinelli, SG, et al. Mesenchymal tumours. In: WHO Classification of Tumours of Female Reproductive Organs. Lyon: IARC, 2014, pp. 122–151.Google Scholar
Prat, J, Mbatani, N. Uterine sarcomas. Int J Gynecol Obstet 2015;131:S105–S110.Google Scholar
Hosh, M, Antar, S, Nazzal, A, et al. Uterine sarcoma: analysis of 13089 cases based on Surveillance, Epidemiology, and End Results Database. Int J Gynecol Cancer 2016;26:1098–1104.Google Scholar
Garret, LA, Harmon, DC, Schorge, JO. Embryonal rhabdomyosarcoma of the uterine corpus. JCO 2013;31:e48–e50.Google Scholar
Ferrari, A, Dileo, P, Casanova, M, et al. Rhabdomyosarcoma in adults: a retrospective analysis of 171 patients treated at a single institution. Cancer 2003;98:571–580.CrossRefGoogle ScholarPubMed
Minard-Colin, V, Walterhouse, D, Bisogno, G, et al. Localized vaginal/uterine rhabdomyosarcoma: results of a pooled analysis from four international cooperative groups. Pediatr Blood Cancer, 2018. doi: 10.1002/pbc.27096.Google Scholar
Felix, AS, Cook, LS, Gaudet, MM, et al. The etiology of uterine sarcomas: a pooled analysis of the epidemiology of endometrial cancer consortium. Br J Cancer 2013;108:727–734.Google Scholar
Pernick, N, Smooth muscle tumors of unknown malignant potential. Available at: www.pathologyoutlines.com/topic/uterusSTUMP.html.Google Scholar
Benson, C, Miah, AB. Uterine sarcoma: current perspectives. Int J Womens Health 2017;9:597–606.Google Scholar
Tropé, CG, Abeler, VM, Kristensen, GB. Diagnosis and treatment of sarcoma of the uterus: a review. Acta Oncol 2012;51:694–705.Google Scholar
Amant, F, Coosemans, A, Debiec-Rychter, M, Timmerman, D, Vergote, I. Clinical management of uterine sarcomas. Lancet Oncol 2009;10:1188–1198.Google Scholar
Goto, A, Takeuchi, S, Sugimura, K, Maruo, T. Usefulness of Gd-DTPA contrast enhanced dynamic MRI and serum determination of LDH and its isozymes in the differential diagnosis of leiomyosarcoma from degenerated leiomyoma of the uterus. Int J Gynecol Cancer 2002;12:354–361.Google Scholar
Sizzi, O, Manganaro, L, Rosetti, A, et al. Assessing the risk of laparoscopic morcellation of occult uterine sarcomas during hysterectomy and myomectomy: literature review and the ISGE recommendations. Eur J Obstet Gynecol Reprod Biol 2018;220:30–38.Google Scholar
Perri, T, Korach, J, Sadetzki, S, et al. Uterine leiomyosarcoma: does the primary surgical procedure matter? Int J Gynecol Cancer 2009;19:257–260.Google Scholar
US Food and Drug Administration, UPDATED laparoscopic uterine power morcellation in hysterectomy and myomectomy. FDA Safety Communication. 2014. Available at: www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm393576.htm.Google Scholar
Harris, JA, Swenson, CW, Uppal, S, et al. Practice patterns and postoperative complications before and after US Food and Drug Administration safety communications on power morcellation. Am J Obstet Gynecol 2016;214:98.e1–98.e13.Google Scholar
Bose, D. Fate of laparoscopic morcellation post-FDA warning: a literature review. Int J Med Res Rev 2016;4:1871–1881.Google Scholar
American College of Obstetricians and Gynecologists. Power Morcellation and Occult Malignancy in Gynecologic Surgery. Washington DC: ACOG, 2014.Google Scholar
Clavero, JM, Deschamps, C, Cassivi, SD, et al. Gynecologic cancers: factors affecting survival after pulmonary metastasectomy. Ann Thorac Surg 2006;81:2004–2007.Google Scholar
Reed, NS, Mangioni, C, Malmström, H, et al. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer 2008;44:808–818.Google Scholar
Malouf, GG, Lhommé, C, Duvillard, P, et al. Prognostic factors and outcome of undifferentiated endometrial sarcoma treated by multimodal therapy. Int J Gynaecol Obstet 2013;122:57–61.Google Scholar
Seagle, BL, Sobecki-Rausch, J, Strohl, AE, et al. Prognosis and treatment of uterine leiomyosarcoma: a National Cancer Database study. Gynecol Oncol 2017;145:61–70.Google Scholar
Desar, IME, Ottevanger, PB, Benson, C, van der Graaf, WTA. Systemic treatment in adult uterine sarcomas. Crit Rev Oncol Hematol 2018;122:10–20.Google Scholar
Seddon, B, Strauss, SJ, Whelan, J, et al. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. Lancet Oncol 2017;18:1397–1410.Google Scholar
Judson, I, Verweij, J, Gelderblom, H, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol 2014;15:415–423.Google Scholar
Thanopoulou, E, Thway, K, Khabra, K, Judson, J. Treatment of hormone positive uterine leiomyosarcoma with aromatase inhibitors. Clin Sarcoma Res 2014;4:5.Google Scholar
Thanopoulou, E, Aleksic, A, Thway, K, Khabra, K, Judson, I. Hormonal treatments in metastatic endometrial stromal sarcomas: the 10-year experience of the sarcoma unit of Royal Marsden Hospital. Clin Sarcoma Res 2015;5:8.Google Scholar
Nakayama, K, Ishikawa, M, Nagai, Y, et al. Prolonged long-term survival of low-grade endometrial stromal sarcoma patients with lung metastasis following treatment with medroxyprogesterone acetate. Int J Clin Oncol 2010;15:179–183.Google Scholar
Tap WD et al. Effect of doxorubicin plus olaratumab vs doxorubicin plus placebo on survival in patients with advanced soft tissue sarcomas. The ANNOUNCE randomized clinical trial. JAMA 2020;323:1266–1276.Google Scholar
Elvin, JA, Gay, LM, Ort, R, et al. Clinical benefit in response to palbociclib treatment in refractory uterine leiomyosarcomas with a common CDKN2A alteration. Oncologist 2017;22:416–421.Google Scholar
van der Graaf, WTA, Blay, J-Y, Chawla, SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012;379:1879–1886.Google Scholar
George, S, Miao, D, Demetri, GD, et al. Loss of PTEN associated with resistance to anti-PD-1 checkpoint blockade therapy in metastatic uterine leiomyosarcoma. Immunity 2017;46: 197–204.CrossRefGoogle ScholarPubMed
Martin-Liberal, J, Benson, C, Messiou, C, Fisher, C, Judson, I. Reversion of hormone treatment resistance with the addition of an mTOR inhibitor in endometrial stromal sarcoma. Case Rep Med 2014. doi:10.1155/2014/612496.Google Scholar
Jimenez, WA, Sardi, A, Nieroda, C, Gushchin, V. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of recurrent high-grade uterine sarcoma with peritoneal dissemination. Am J Obstet Gynecol 2014;210:259e1–259e8.Google Scholar
Carroll, A, Ramirez, PT, Westin, SN, et al. Uterine adenosarcoma: an analysis on management, outcome and risk factors for recurrence. Gynecol Oncol 2014;135:455–461.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×